Buying BioCryst Pharmaceuticals Inc. (BCRX) Stock Is A Smart Move Today?


BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) finished Wednesday with a subtraction of -$0.32 to close at $13.05, a downside of -2.39 percent. An average of 3,269,220 shares of common stock have been traded in the last five days. There was a fall of -$0.44 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 2,418,065 shares traded, while the 50-day average volume stands at 2,626,666.

BCRX stock has decreased by -6.65% in the last month. The company shares reached their 1-month lowest point of $12.55 on 09/16/22. With the stock rallying to its 52-week high on 02/16/22, shares of the company touched a low of $7.61 and a high of $19.99 in 52 weeks. It has reached a new high 8 times so far this year and lost -5.78% or -$0.80 in price. In spite of this, the price is down -34.72% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

157 days have passed since BioCryst Pharmaceuticals Inc. (BCRX) last reported insider trading activity. ABERCROMBIE GEORGE B, who is Director, most recently acquired $5,000 shares at $11.04 per share on Apr 18. In this transaction, the insider spent $55,200. Chief R&D Officer, Thackray Helen M., disposed of 7,600 shares at a price of $16.20 on Apr 01. The insider now owns more than $123,120 worth of shares. Prior to that, Chief Medical Officer Sheridan William P went on to Sale 161,139 shares at $16.88 each on Mar 10. An amount of $2,719,493 was transacted.

Valuation Metrics

BioCryst Pharmaceuticals Inc. (BCRX) stock’s beta is 2.09. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.63.

Financial Health

The quick ratio of BioCryst Pharmaceuticals Inc. for the three months ended March 30 was 4.90, and the current ratio was 5.20, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $149.94 million compared to revenue of $157.17 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, BioCryst Pharmaceuticals Inc.’s return on assets was -44.30%.

Earnings Surprise

For the three-month period that ended March 30, BioCryst Pharmaceuticals Inc. had $144.91 million in cash and short-term investments compared to $144.52 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$58.86 million in the quarter, while revenues of -$74.2 million were grew 26.61%. The analyst consensus anticipated BioCryst Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.37 per share, but it turned out to be -$0.4, a -8.10% surprise. For the quarter, EBITDA amounted to -$34.51 million. Shareholders own equity worth $185.94 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at BioCryst Pharmaceuticals Inc. (BCRX) price momentum. RSI 9-day as of the close on 21 September was 41.31%, suggesting the stock is Neutral, with historical volatility in this time frame at 48.10%.

As of today, BCRX’s price is $13.20 -3.26% or -$0.44 from its 5-day moving average. BCRX is currently trading -9.69% lower than its 20-day SMA and +34.95% higher than its 100-day SMA. However, the stock’s current price level is +16.10% above the SMA50 and +14.07% above the SMA200.

The stochastic %K and %D were 40.38% and 37.13%, respectively, and the average true range (ATR) was 0.65. With the 14-day stochastic at 25.77% and the average true range at 0.65, the RSI (14) stands at 44.87%. The stock has reached 0.01 on the 9-day MACD Oscillator while the 14-day reading was at -0.18.

Analyst Ratings

Oppenheimer downgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) to a a Perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for BioCryst Pharmaceuticals Inc. (BCRX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BCRX, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.

What is BCRX’s price target for the next 12 months?

Analysts predict a range of price targets between $14.00 and $30.00, with a median target of $16.00. Taking a look at these predictions, the average price target given by analysts for BioCryst Pharmaceuticals Inc. (BCRX) stock is $18.30.


Please enter your comment!
Please enter your name here